Sequential serological responses to Aspergillus fumigatus in patients with cystic fibrosis. Use of antigen 'stretching' to delineate IgG and IgE activity.
Immunogens from Aspergillus fumigatus were fractionated on the basis of molecular weight. Nine fractions ranging from 900 to 10 kDa were used in ELISA and in a radioallergosorbent test (RAST) with sera from cases of allergic bronchopulmonary aspergillosis (ABPA) and from cystic fibrosis (CF) patients with ABPA or other Aspergillus involvement and compared with control subjects. The profile of IgG reactivity to the nine fractions did not vary substantially for all Aspergillus-involved groups producing peaks at greater than 900 kD and 170 kD whereas the profile for control subjects had a peak at greater than 900 kD only. The IgE profile for CF patients with ABPA did not differ from the profile of the RAST-positive CF patients without ABPA and provided only one peak of activity at 24 kD. Recovery from an episode of ABPA in CF patients was accompanied by a fall in both IgG and IgE antibody levels to all nine fractions, whereas increases in IgG and IgE to all fractions were seen during an episode of ABPA. Although there was an exaggerated IgG increase to antigens in the 43-170 kD range during ABPA, a meaningful increase was also observed to unfractionated A. fumigatus antigen preparations. With IgE in one detailed study the 24-kD fraction provided a better indication of Aspergillus involvement than the unfractionated A. fumigatus antigens. Sequential studies of IgG and IgE levels were not able to predict an episode of ABPA but were useful in conjunction with clinical assessment in following the course of the illness.
Edwards
J H
JH
Department of Medical Microbiology, University of Wales College of Medicine, Cardiff, UK.
Alfaham
M
M
Fifield
R
R
Philpot
C
C
Clement
M J
MJ
Goodchild
M C
MC
D000293:Adolescent; D000328:Adult; D000908:Antibodies, Fungal / Q000276:immunology*; D000946:Antigens, Fungal / Q000276:immunology*; D001228:Aspergillosis / Q000188:drug therapy / Q000276:immunology; D001232:Aspergillus fumigatus / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007223:Infant; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D008825:Miconazole / Q000627:therapeutic use; D008970:Molecular Weight; D013997:Time Factors
D000908:Antibodies, Fungal; D000946:Antigens, Fungal; D007074:Immunoglobulin G; D017964:Itraconazole; D007073:Immunoglobulin E; D008825:Miconazole; D007654:Ketoconazole